BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 35709779)

  • 21. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care.
    Bergram M; Nasr P; Iredahl F; Kechagias S; Rådholm K; Ekstedt M
    Scand J Gastroenterol; 2022 Jan; 57(1):60-69. PubMed ID: 34618619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value.
    Higuera-de-la-Tijera F; Córdova-Gallardo J; Buganza-Torio E; Barranco-Fragoso B; Torre A; Parraguirre-Martínez S; Rojano-Rodríguez ME; Quintero-Bustos G; Castro-Narro G; Moctezuma-Velazquez C
    Dig Dis Sci; 2021 Dec; 66(12):4501-4507. PubMed ID: 33428035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
    Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
    Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
    Roeb E
    Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.
    Lee H; Kim G; Choi YJ; Huh BW; Lee BW; Kang ES; Cha BS; Lee EJ; Lee YH; Huh KB
    Diabetes Metab J; 2020 Apr; 44(2):267-276. PubMed ID: 30877708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
    Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
    Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
    Méndez-Sánchez N; Díaz-Orozco LE
    Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Alcoholic Fatty Liver Disease.
    Brůha R
    Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review).
    Bica C; Sandu C; Suceveanu AI; Sarbu E; Stoica RA; Gherghiceanu F; Bohiltea RE; Stefan SD; Stoian AP
    Exp Ther Med; 2020 Sep; 20(3):2387-2391. PubMed ID: 32765720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N; Häring HU; Cusi K
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
    Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
    Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of non-alcoholic fatty liver disease.
    Jennison E; Patel J; Scorletti E; Byrne CD
    Postgrad Med J; 2019 Jun; 95(1124):314-322. PubMed ID: 31085617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
    Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
    Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.
    Colosimo S; Ravaioli F; Petroni ML; Brodosi L; Marchignoli F; Barbanti FA; Sasdelli AS; Marchesini G; Pironi L
    Liver Int; 2021 Apr; 41(4):731-742. PubMed ID: 33497019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-alcoholic steatohepatitis - from NAFLD to MAFLD].
    Balmer ML; Dufour JF
    Ther Umsch; 2011 Apr; 68(4):183-8. PubMed ID: 21452138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients.
    Lu W; Li S; Li Y; Zhou J; Wang K; Chen N; Li Z
    BMC Endocr Disord; 2024 Jun; 24(1):84. PubMed ID: 38849804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
    Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
    Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.